Petros Pharmaceuticals, Inc. (PTPI)

0.00 +0.00% (+0.00)

Over 3Y: -100.0%

2026-08-28
20 40 60
2023 2024 2025 2026

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q3 '21 — Revenue: 2.1M Q3 '21 — Operating Cash Flow: -1.2M Q3 '21 — Net Income: -1.7M Q4 '21 — Operating Cash Flow: -8.3M Q4 '21 — Net Income: -8.2M Q1 '22 — Revenue: 2.5M Q1 '22 — Operating Cash Flow: -5.3M Q1 '22 — Net Income: -174.2K Q2 '22 — Revenue: 4.2M Q2 '22 — Operating Cash Flow: -4.2M Q2 '22 — Net Income: -1.8M Q3 '22 — Revenue: -1.5M Q3 '22 — Operating Cash Flow: -1.8M Q3 '22 — Net Income: -13.8M Q4 '22 — Revenue: 798.1K Q4 '22 — Operating Cash Flow: -1.6M Q4 '22 — Net Income: -4.2M Q1 '23 — Revenue: 2.5M Q1 '23 — Operating Cash Flow: -748.4K Q1 '23 — Net Income: -1.4M Q2 '23 — Revenue: 2M Q2 '23 — Operating Cash Flow: -572.1K Q2 '23 — Net Income: -2.5M Q3 '23 — Revenue: 1.7M Q3 '23 — Operating Cash Flow: -4M Q3 '23 — Net Income: -4.5M Q4 '23 — Operating Cash Flow: -2.3M Q4 '23 — Net Income: 318.1K Q1 '24 — Revenue: 1.4M Q1 '24 — Operating Cash Flow: -1.1M Q1 '24 — Net Income: -2.2M Q2 '24 — Revenue: 1.4M Q2 '24 — Operating Cash Flow: -1.7M Q2 '24 — Net Income: -662K Q3 '24 — Revenue: 1.6M Q3 '24 — Operating Cash Flow: -771.2K Q3 '24 — Net Income: -2.2M Q4 '24 — Revenue: 725.4K Q4 '24 — Operating Cash Flow: -390.6K Q4 '24 — Free Cash Flow: -396.1K Q4 '24 — Net Income: -9.3M Q1 '25 — Operating Cash Flow: -1.7M Q1 '25 — Net Income: -2.3M Q2 '25 — Operating Cash Flow: -3M Q2 '25 — Net Income: 5.4M Q3 '25 — Operating Cash Flow: -1.1M Q3 '25 — Net Income: -922.7K Q4 '25 — Operating Cash Flow: -933.5K Q4 '25 — Net Income: -336.5K Q1 '26 — Operating Cash Flow: -784.3K Q1 '26 — Net Income: -987K Q2 '26 — Operating Cash Flow: -863.9K Q2 '26 — Net Income: -955.6K -12M -8M -4M 0 4M 8M
Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2024-12-31, reported in USD. The newest fact in the filings is dated 2026-06-30, 61 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

8.1
Gross margin 76.3%
Accruals —
EBITDA margin —
FCF margin —
OCF / EBIT —
OCF margin —
OE margin —
Oper. margin —
Profit margin —
ROA —
ROCE —
ROE —
ROIC —

1 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

1.0
RPO / sales —
RPO growth —
Segment HHI —

3 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

5.5
ND/EBITDA —
Debt / Eq 0.0×
Debt payback 0.0 yr
Quick ratio 0.77×
F-score 3.4 pts
Cash / Debt —
Cash runway —
Interest cover —
Payout —

2 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

1.0
Sales CAGR 4Y -14.5%
Sales/sh Y/Y -99.2%
Shares change +8668.8%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —
Sales Q/Q —

2 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.